BNP Paribas Financial Markets Has $6.43 Million Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

BNP Paribas Financial Markets lessened its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTXFree Report) by 67.7% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 78,414 shares of the biotechnology company’s stock after selling 164,011 shares during the quarter. BNP Paribas Financial Markets owned about 0.07% of Viking Therapeutics worth $6,430,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of VKTX. American Century Companies Inc. lifted its stake in shares of Viking Therapeutics by 59.6% during the 3rd quarter. American Century Companies Inc. now owns 2,202,228 shares of the biotechnology company’s stock worth $24,379,000 after buying an additional 822,156 shares during the last quarter. Citigroup Inc. raised its stake in Viking Therapeutics by 73.1% in the 3rd quarter. Citigroup Inc. now owns 359,585 shares of the biotechnology company’s stock worth $3,981,000 after purchasing an additional 151,826 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in Viking Therapeutics in the 3rd quarter worth about $2,373,000. Vanguard Group Inc. raised its stake in Viking Therapeutics by 3.4% in the 3rd quarter. Vanguard Group Inc. now owns 5,284,352 shares of the biotechnology company’s stock worth $58,498,000 after purchasing an additional 171,995 shares in the last quarter. Finally, Legato Capital Management LLC acquired a new stake in Viking Therapeutics in the 4th quarter worth about $611,000. Institutional investors and hedge funds own 76.03% of the company’s stock.

Viking Therapeutics Price Performance

NASDAQ:VKTX opened at $57.99 on Thursday. The company has a market cap of $6.39 billion, a PE ratio of -62.35 and a beta of 1.03. Viking Therapeutics, Inc. has a one year low of $8.28 and a one year high of $99.41. The firm’s 50 day simple moving average is $60.44 and its 200 day simple moving average is $53.38.

Viking Therapeutics (NASDAQ:VKTXGet Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. During the same quarter last year, the company posted ($0.25) earnings per share. Equities research analysts expect that Viking Therapeutics, Inc. will post -1.11 EPS for the current year.

Insider Transactions at Viking Therapeutics

In other news, COO Marianna Mancini sold 281,425 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $78.66, for a total value of $22,136,890.50. Following the transaction, the chief operating officer now owns 348,508 shares in the company, valued at approximately $27,413,639.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Greg Zante sold 66,756 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $74.69, for a total transaction of $4,986,005.64. Following the transaction, the chief financial officer now owns 174,854 shares in the company, valued at approximately $13,059,845.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Marianna Mancini sold 281,425 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $78.66, for a total transaction of $22,136,890.50. Following the transaction, the chief operating officer now owns 348,508 shares in the company, valued at approximately $27,413,639.28. The disclosure for this sale can be found here. Corporate insiders own 4.70% of the company’s stock.

Analyst Ratings Changes

VKTX has been the subject of several analyst reports. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a research note on Thursday, June 27th. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Viking Therapeutics in a research note on Monday, June 24th. Maxim Group reiterated a “buy” rating and issued a $120.00 price objective on shares of Viking Therapeutics in a research note on Tuesday, June 4th. Raymond James reissued a “strong-buy” rating on shares of Viking Therapeutics in a report on Tuesday, June 4th. Finally, BTIG Research raised their target price on shares of Viking Therapeutics from $100.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Viking Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $111.56.

View Our Latest Stock Analysis on Viking Therapeutics

About Viking Therapeutics

(Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Featured Stories

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.